Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P06126
UPID:
CD1A_HUMAN
Alternative names:
T-cell surface antigen T6/Leu-6
Alternative UPACC:
P06126; D3DVD7; Q13962; Q5TDJ8; Q9UMM4; Q9Y5M5
Background:
T-cell surface glycoprotein CD1a, also known as T-cell surface antigen T6/Leu-6, plays a pivotal role in the immune system. It is an antigen-presenting protein that binds both self and non-self lipid and glycolipid antigens, presenting them to T-cell receptors on natural killer T-cells. This process is crucial for the activation and regulation of natural killer T-cells, which are integral to the body's defense mechanisms against pathogens and malignancies.
Therapeutic significance:
Understanding the role of T-cell surface glycoprotein CD1a could open doors to potential therapeutic strategies. Its critical function in presenting antigens to natural killer T-cells highlights its potential as a target for immunotherapy treatments, aiming to enhance the body's natural defense mechanisms against various diseases.